Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer Journal Article

   


Authors: Hellmann, M. D.; Callahan, M. K.; Awad, M. M.; Calvo, E.; Ascierto, P. A.; Atmaca, A.; Rizvi, N. A.; Hirsch, F. R.; Selvaggi, G.; Szustakowski, J. D.; Sasson, A.; Golhar, R.; Vitazka, P.; Chang, H.; Geese, W. J.; Antonia, S. J.
Article Title: Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer
Abstract: Durable responses and encouraging survival have been demonstrated with immune checkpoint inhibitors in small-cell lung cancer (SCLC), but predictive markers are unknown. We used whole exome sequencing to evaluate the impact of tumor mutational burden on efficacy of nivolumab monotherapy or combined with ipilimumab in patients with SCLC from the nonrandomized or randomized cohorts of CheckMate 032. Patients received nivolumab (3 mg/kg every 2 weeks) or nivolumab plus ipilimumab (1 mg/kg plus 3 mg/kg every 3 weeks for four cycles, followed by nivolumab 3 mg/kg every 2 weeks). Efficacy of nivolumab ± ipilimumab was enhanced in patients with high tumor mutational burden. Nivolumab plus ipilimumab appeared to provide a greater clinical benefit than nivolumab monotherapy in the high tumor mutational burden tertile. Hellmann et al. evaluate the impact of tumor mutational burden on the efficacy of nivolumab monotherapy or combination with ipilimumab in patients with small-cell lung cancer (SCLC). They show that treatment efficacy and the increased benefit of the combination are most substantial in SCLC with high tumor mutational burden. © 2018 Elsevier Inc.
Keywords: clinical trial; biomarkers; ipilimumab; immunotherapy; ctla-4; pd-1; small cell lung cancer; nivolumab; tumor mutation burden
Journal Title: Cancer Cell
Volume: 33
Issue: 5
ISSN: 1535-6108
Publisher: Cell Press  
Date Published: 2018-05-14
Start Page: 853
End Page: 861.e4
Language: English
DOI: 10.1016/j.ccell.2018.04.001
PROVIDER: scopus
PUBMED: 29731394
PMCID: PMC6750707
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85045874395&doi=10.1016%2fj.ccell.2018.04.001&partnerID=40&md5=fce049e0a3cace110c96d4e88b6be0cf
Notes: Article -- Export Date: 1 June 2018 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Margaret Kathleen Callahan
    197 Callahan
  2. Matthew David Hellmann
    411 Hellmann
Related MSK Work